edotecarin (J 107088)

Also Known As:

J 107088; 12-beta-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione; 6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy-13-glucopyranosyl-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)dione; J-107088; J107088

Networked: 14 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Carbazoles: 32
        edotecarin: 14
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 32
      - edotecarin: 14

Experts

1.	Diasio, Robert B: 2 articles (08/2010 - 05/2005)
2.	Ciomei, Marina: 2 articles (07/2007 - 05/2006)
3.	Croci, Valter: 2 articles (07/2007 - 05/2006)
4.	Pesenti, Enrico: 2 articles (07/2007 - 05/2006)
5.	McGovren, J Patrick: 2 articles (01/2007 - 08/2006)
6.	Natsumeda, Yutaka: 2 articles (01/2007 - 08/2006)
7.	Douillard, Jean-Yves: 1 article (08/2010)
8.	Saif, Muhammad Wasif: 1 article (08/2010)
9.	Sellers, Sandra: 1 article (08/2010)
10.	Arakawa, Hiroharu: 1 article (05/2009)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2006 - "This study aimed to determine the maximum tolerated dose (MTD), the recommended dose for future Phase II studies and the safety, pharmacokinetic profile, and preliminary antitumor activity of edotecarin in a population of patients with advanced solid tumors. " 01/01/2007 - "Twenty-nine patients (18M:11F) received a 2-h IV infusion of edotecarin in doses of 6, 8, 11, 13, or 15 mg/m(2) every 21 days (with an additional 1-2 weeks permitted for recovery) and were evaluated for safety, PK, and tumor response. " 08/01/2006 - "Edotecarin was administered as a single dose by IV infusion over 2 h every 21 days (with 1 week permitted for recovery from toxicities, if needed) in patients with advanced solid tumors. " 05/01/2006 - "Edotecarin also possesses greater than additive inhibitory effects on cell proliferation when used in combination with other agents tested in vitro against various cancer cell lines. " 10/01/1999 - "Therefore, J-107088 is considered to be a promising candidate as an anti-tumor drug for treatment of solid tumors in humans."
2.	Neoplasm Metastasis (Metastasis) 10/01/1999 - "Furthermore, J-107088 was found to be highly effective in inhibiting proliferation of micro-metastases of tumors to the liver in mice. "
3.	Colonic Neoplasms (Colon Cancer) 05/01/2006 - "The results suggest that edotecarin may serve as effective chemotherapy of colon cancer when used as a single agent, in combination with standard regimens and other topoisomerase inhibitors or with novel agents, such as the multitargeted tyrosine kinase inhibitor SU11248." 05/01/2006 - "The present in vivo studies were done to extend the in vitro findings to characterize the antitumor effects of edotecarin when used either alone or in combination with other agents (i.e., 5-fluorouracil, irinotecan, cisplatin, oxaliplatin, and SU11248) in the HCT-116 human colon cancer xenograft model. "
4.	Brain Neoplasms (Brain Tumor) 09/01/2001 - "These results indicate that J-107088 may be active in the treatment of childhood and adult malignant brain tumors and provide the rationale for initiation of clinical trials with this agent."
5.	Breast Neoplasms (Breast Cancer) 07/01/2007 - "Edotecarin inhibited cellular proliferation in breast carcinoma cell lines: 50% inhibitory concentrations ranged from 8 nmol/L in SKBR-3 cells to approximately 30 micromol/L in BT20 cells. " 07/01/2007 - "Antitumor activity of edotecarin in breast carcinoma models." 07/01/2007 - "The data suggest that edotecarin may be useful as a single agent or a component of combination chemotherapy regimens for treating human breast cancer." 05/28/2009 - "Among them, the three most potent pyridylmethyl analogues, compounds 22g, 22m, and 23c, showed better antitumor activities against MKN-45 human stomach cancer or MX-1 human breast cancer xenografted mice than those of edotecarin. " 07/01/2007 - "Edotecarin also exhibited potent antitumor activity against xenografted human MX-1 cells, MMTV-v-Ha-ras oncogene-driven mouse breast tumors, and chemically induced rat mammary tumors. "

Related Drugs and Biologics

1.	Topoisomerase I Inhibitors
2.	Fluorouracil (Carac)
3.	Cisplatin (Platino)
4.	Leucovorin (Folinic Acid)
5.	Sunitinib (Sutent)
6.	Oxaliplatin (Eloxatin)
7.	Irinotecan (Camptosar)
8.	NB 506
9.	Type I DNA Topoisomerases (Topoisomerase I)
10.	carbazole

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Injections
4.	Combination Drug Therapy (Combination Chemotherapy)